Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2007

Metabolic imaging using PET

Author: Takashi Kudo

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2007

Abstract

Introduction

There is growing evidence that myocardial metabolism plays a key role not only in ischaemic heart disease but also in a variety of diseases which involve myocardium globally, such as heart failure and diabetes mellitus. Understanding myocardial metabolism in such diseases helps to elucidate the pathophysiology and assists in making therapeutic decisions.

Measurement

As well as providing information on regional changes, PET can deliver quantitative information about both regional and global changes in metabolism. This capability of quantitative measurement is one of the major advantages of PET along with physiological positron tracers, especially relevant in evaluating diseases which involve the whole myocardium.

Discussion

This review discusses major PET tracers for metabolic imaging and their clinical applications and contributions to research regarding ischaemic heart disease and other diseases such as heart failure and diabetic heart disease. Future applications of positron metabolic tracers for the detection of vulnerable plaque are also highlighted briefly.

Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [¹⁴C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897–916.CrossRef

Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371–88.PubMedCrossRef

Krivokapich J, Huang SC, Phelps ME, Barrio JR, Watanabe CR, Selin CE, et al. Estimation of rabbit myocardial metabolic rate for glucose using fluorodeoxyglucose. Am J Physiol 1982;243:H884–95.PubMed

Krivokapich J, Huang SC, Selin CE, Phelps ME. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol 1987;252:H777–87.PubMed

Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 1989;30:359–66.PubMed

Choi Y, Hawkins RA, Huang SC, Gambhir SS, Brunken RC, Phelps ME, et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[¹⁸F]fluoro-2-deoxy-d-glucose studies. J Nucl Med 1991;32:733–8.PubMed

Virtanen KA, Peltoniemi P, Marjamaki P, Asola M, Strindberg L, Parkkola R, et al. Human adipose tissue glucose uptake determined using [¹⁸F]-fluoro-deoxy-glucose ([¹⁸F]FDG) and PET in combination with microdialysis. Diabetologia 2001;44:2171–9.PubMedCrossRef

Botker HE, Bottcher M, Schmitz O, Gee A, Hansen SB, Cold GE, et al. Glucose uptake and lumped constant variability in normal human hearts determined with [¹⁸F]fluorodeoxyglucose. J Nucl Cardiol 1997;4:125–32.PubMedCrossRef

Tamaki N, Kawamoto M, Takahashi N, Yonekura Y, Magata Y, Torizuka T, et al. Assessment of myocardial fatty acid metabolism with positron emission tomography at rest and during dobutamine infusion in patients with coronary artery disease. Am Heart J 1993;125:702–10.PubMedCrossRef

10.

Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996;37:1723–30.PubMed

11.

Schon HR, Schelbert HR, Robinson G, Najafi A, Huang SC, Hansen H, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C-11 palmitic acid in normal myocardium. Am Heart J 1982;103:532–47.PubMedCrossRef

12.

DeGrado TR, Coenen HH, Stocklin G. 14(R,S)-[¹⁸F]fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med 1991;32:1888–96.PubMed

13.

Ebert A, Herzog H, Stocklin GL, Henrich MM, DeGrado TR, Coenen HH, et al. Kinetics of 14(R,S)-fluorine-18-fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. J Nucl Med 1994;35:51–6.PubMed

14.

Altehoefer C, vom Dahl J, Bares R, Stocklin GL, Bull U. Metabolic mismatch of septal beta-oxidation and glucose utilization in left bundle branch block assessed with PET. J Nucl Med 1995;36:2056–9.PubMed

15.

Takala TO, Nuutila P, Pulkki K, Oikonen V, Gronroos T, Savunen T, et al. 14(R,S)-[¹⁸F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging 2002;29:1617–22.PubMedCrossRef

16.

Degrado TR, Kitapci MT, Wang S, Ying J, Lopaschuk GD. Validation of¹⁸F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J Nucl Med 2006;47:173–81.PubMed

17.

DeGrado TR, Wang S, Rockey DC. Preliminary evaluation of 15-[¹⁸F]fluoro-3-oxa-pentadecanoate as a PET tracer of hepatic fatty acid oxidation. J Nucl Med 2000;41:1727–36.PubMed

18.

Shoup TM, Elmaleh DR, Bonab AA, Fischman AJ. Evaluation of trans-9-¹⁸F-fluoro-3,4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 2005;46:297–304.PubMed

19.

Renstrom B, Rommelfanger S, Stone CK, DeGrado TR, Carlson KJ, Scarbrough E, et al. Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. J Nucl Med 1998;39:1684–9.PubMed

20.

Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 1987;76:687–96.PubMed

21.

Tamaki N, Magata Y, Takahashi N, Kawamoto M, Torizuka T, Yonekura Y, et al. Myocardial oxidative metabolism in normal subjects in fasting, glucose loading and dobutamine infusion states. Ann Nucl Med 1992;6:221–8.PubMed

22.

Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1-¹¹C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation. 1990;81:1594–605.PubMed

23.

Gropler RJ, Siegel BA, Geltman EM. Myocardial uptake of carbon-11-acetate as an indirect estimate of regional myocardial blood flow. J Nucl Med 1991;32:245–51.PubMed

24.

Sciacca RR, Akinboboye O, Chou RL, Epstein S, Bergmann SR. Measurement of myocardial blood flow with PET using 1-¹¹C-acetate. J Nucl Med 2001;42:63–70.PubMed

25.

Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 1998;39:272–80.PubMed

26.

van den Hoff J, Burchert W, Borner AR, Fricke H, Kuhnel G, Meyer GJ, et al. [1-¹¹C]Acetate as a quantitative perfusion tracer in myocardial PET. J Nucl Med 2001;42:1174–82.PubMed

27.

Feng B, Pretorius PH, Farncombe TH, Dahlberg ST, Narayanan MV, Wernick MN, et al. Simultaneous assessment of cardiac perfusion and function using 5-dimensional imaging with Tc-99m teboroxime. J Nucl Cardiol 2006;13:354–61.PubMedCrossRef

28.

Porenta G, Cherry S, Czernin J, Brunken R, Kuhle W, Hashimoto T, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med 1999;26:1465–74.PubMedCrossRef

29.

Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8.PubMedCrossRef

30.

de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging 2005;32:98–101.PubMedCrossRef

31.

Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006;20:203–8.PubMed

32.

Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749–56.PubMed

33.

Hicks RJ, Herman WH, Kalff V, Molina E, Wolfe ER, Hutchins G, et al. Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol 1991;18:101–11.PubMedCrossRef

34.

Pagano D, Lewis ME, Townend JN, Davies P, Camici PG, Bonser RS. Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival. Heart 1999;82:684–8.PubMed

35.

Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging 2002;29:721–7.PubMedCrossRef

36.

Knuuti MJ, Nuutila P, Ruotsalainen U, Teras M, Saraste M, Harkonen R, et al. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. J Nucl Med 1993;34:2068–75.PubMed

37.

Morita K, Katoh C, Yoshinaga K, Noriyasu K, Mabuchi M, Tsukamoto T, et al. Quantitative analysis of myocardial glucose utilization in patients with left ventricular dysfunction by means of¹⁸F-FDG dynamic positron tomography and three-compartment analysis. Eur J Nucl Med Mol Imaging. 2005;32:806–12.PubMedCrossRef

38.

Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60–9.PubMedCrossRef

39.

Bax JJ, Visser FC, Elhendy A, Poldermans D, Cornel JH, van Lingen A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med 1999;40:1866–73.PubMed

40.

Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004;25:815–36.PubMedCrossRef

41.

Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451–60.PubMedCrossRef

42.

Barrington SF, Chambers J, Hallett WA, O’Doherty MJ, Roxburgh JC, Nunan TO. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging 2004;31:355–61.PubMedCrossRef

43.

Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001;37:81–8.PubMedCrossRef

44.

Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2002;29:1257–66.PubMedCrossRef

45.

Bacharach SL, Bax JJ, Case J, Delbeke D, Kurdziel KA, Martin WH, et al. American Society of Nuclear Cardiology practice guidelines. J Nucl Cardiol 2003;10:543–56.PubMedCrossRef

46.

Schelbert HR, Beanlands R, Bengel F, Knuuti J, DiCarli M, Machac J, et al. PET myocardial perfusion and glucose metabolism imaging: part 2—guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557–71.PubMedCrossRef

47.

Schaefer WM, Lipke CS, Nowak B, Kaiser HJ, Buecker A, Krombach GA, et al. Validation of an evaluation routine for left ventricular volumes, ejection fraction and wall motion from gated cardiac FDG PET: a comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2003;30:545–53.PubMedCrossRef

48.

Saab G, Dekemp RA, Ukkonen H, Ruddy TD, Germano G, Beanlands RS. Gated fluorine 18 fluorodeoxyglucose positron emission tomography: determination of global and regional left ventricular function and myocardial tissue characterization. J Nucl Cardiol 2003;10:297–303.PubMedCrossRef

49.

Santana CA, Shaw LJ, Garcia EV, Soler-Peter M, Candell-Riera J, Grossman GB, et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J Nucl Cardiol 2004;11:542–50.PubMedCrossRef

50.

Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, de Boer J, et al. Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. J Nucl Cardiol 2006;13:210–9.PubMedCrossRef

51.

Yamakawa Y, Takahashi N, Ishikawa T, Uchino K, Mochida Y, Ebina T, et al. Clinical usefulness of ECG-gated¹⁸F-FDG PET combined with^99mTc-MIBI gated SPECT for evaluating myocardial viability and function. Ann Nucl Med 2004;18:375–83.PubMedCrossRef

52.

Bax JJ, Visser FC, van Lingen A, Huitink JM, Kamp O, van Leeuwen GR, et al. Feasibility of assessing regional myocardial uptake of¹⁸F-fluorodeoxyglucose using single photon emission computed tomography. Eur Heart J 1993;14:1675–82.PubMed

53.

Drane WE, Abbott FD, Nicole MW, Mastin ST, Kuperus JH. Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress. Radiology 1994;191:461–5.PubMed

54.

Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176–9.PubMed

55.

Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A, Huitink JM, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997;30:377–83.PubMedCrossRef

56.

Chen EQ, MacIntyre WJ, Go RT, Brunken RC, Saha GB, Wong CY, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997;38:582–6.PubMed

57.

Mabuchi M, Kubo N, Morita K, Noriyasu K, Itoh Y, Katoh C, et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Commun 2002;23:879–85.PubMedCrossRef

58.

Fukuchi K, Katafuchi T, Fukushima K, Shimotsu Y, Toba M, Hayashida K, et al. Estimation of myocardial perfusion and viability using simultaneous^99mTc-tetrofosmin-FDG collimated SPECT. J Nucl Med 2000;41:1318–23.PubMed

59.

Matsunari I, Kanayama S, Yoneyama T, Matsudaira M, Nakajima K, Taki J, et al. Electrocardiographic-gated dual-isotope simultaneous acquisition SPECT using¹⁸F-FDG and^99mTc-sestamibi to assess myocardial viability and function in a single study. Eur J Nucl Med Mol Imaging 2005;32:195–202.PubMedCrossRef

60.

Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Moerlein SM, Sobel BE, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992;20:569–77.PubMedCrossRef

61.

Hata T, Nohara R, Fujita M, Hosokawa R, Lee L, Kudo T, et al. Noninvasive assessment of myocardial viability by positron emission tomography with¹¹C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation 1996;94:1834–41.PubMed

62.

Yoshinaga K, Katoh C, Beanlands RS, Noriyasu K, Komuro K, Yamada S, et al. Reduced oxidative metabolic response in dysfunctional myocardium with preserved glucose metabolism but with impaired contractile reserve. J Nucl Med 2004;45:1885–91.PubMed

63.

Miyabe H, Ohte N, Iida A, Narita H, Yoshida T, Kimura G. Evaluation of fatty acid beta-oxidation in patients with prior myocardial infarction in relation to myocardial blood flow, total oxidative metabolism, and left ventricular wall motion. Circ J 2005;69:1459–65.PubMedCrossRef

64.

Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [¹⁸F]fluoro-6-thia-heptadecanoic acid and [¹⁸F]FDG in patients with congestive heart failure. J Nucl Med 2001;42:55–62.PubMed

65.

Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441–6.PubMed

66.

Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271–7.PubMedCrossRef

67.

Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.PubMedCrossRef

68.

Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98:14J–18J.PubMedCrossRef

69.

Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161–5.PubMedCrossRef

70.

Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27–35.CrossRef

71.

Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280–8.PubMedCrossRef

72.

Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005;112:3218–21.PubMedCrossRef

73.

Lopaschuk GD. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 2006;10:228–30.PubMedCrossRef

74.

Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114:2130–7.PubMedCrossRef

75.

Torizuka T, Tamaki N, Kasagi K, Misaki T, Kawamoto M, Tadamura E, et al. Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon-11-acetate. J Nucl Med 1995;36:1981–6.PubMed

76.

Hattori N, Tamaki N, Kudoh T, Masuda I, Magata Y, Kitano H, et al. Abnormality of myocardial oxidative metabolism in noninsulin-dependent diabetes mellitus. J Nucl Med 1998;39:1835–40.PubMed

77.

Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389–98.PubMedCrossRef

78.

Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070–5.PubMed

79.

Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate-comparison between the normal and failing human heart. Eur J Nucl Med 2000;27:319–26.PubMedCrossRef

80.

Nowak B, Sinha AM, Schaefer WM, Koch KC, Kaiser HJ, Hanrath P, et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2003;41:1523–8.PubMedCrossRef

81.

Knuuti J, Sundell J, Naum A, Engblom E, Koistinen J, Ylitalo A, et al. Assessment of right ventricular oxidative metabolism by PET in patients with idiopathic dilated cardiomyopathy undergoing cardiac resynchronization therapy. Eur J Nucl Med Mol Imaging 2004;31:1592–8.PubMedCrossRef

82.

Lindner O, Sorensen J, Vogt J, Fricke E, Baller D, Horstkotte D, et al. Cardiac efficiency and oxygen consumption measured with¹¹C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med 2006;47:378–83.PubMed

83.

Lindner O, Vogt J, Kammeier A, Fricke E, Holzinger J, Lamp B, et al. Cardiac re-synchronization therapy: effects on myocardial perfusion at rest, after vasodilation and oxygen consumption. Nuklearmedizin 2006;45:10–14.PubMed

84.

van Campen CM, Visser FC, van der Weerdt AP, Knaapen P, Comans EF, Lammertsma AA, et al. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging 2007;34:309–15.PubMedCrossRef

85.

Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, et al. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med 2006;47:1565–70.PubMed

86.

Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104–13.PubMed

87.

Li SH, McNeill JH. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001;217:121–9.PubMedCrossRef

88.

Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006;47:598–604.PubMedCrossRef

89.

Knuuti J, Takala TO, Nagren K, Sipila H, Turpeinen AK, Uusitupa MI, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001;44:184–7.PubMedCrossRef

90.

Turpeinen AK, Takala TO, Nuutila P, Axelin T, Luotolahti M, Haaparanta M, et al. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[¹⁸F]fluoro-6-thia-heptadecanoic acid. Diabetes 1999;48:1245–50.PubMedCrossRef

91.

Turpeinen AK, Kuikka JT, Vanninen E, Uusitupa MI. Abnormal myocardial kinetics of¹²³I-heptadecanoic acid in subjects with impaired glucose tolerance. Diabetologia 1997;40:541–9.PubMedCrossRef

92.

Coort SL, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem 2006 Sep 19; [Epub ahead of print].

93.

McMillin JB, Taffet GE, Taegtmeyer H, Hudson EK, Tate CA. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 1993;27:2222–8.PubMedCrossRef

94.

Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [¹⁸F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.PubMedCrossRef

95.

Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo¹⁸F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818–24.PubMedCrossRef

96.

Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825–31.PubMedCrossRef

97.

Mukai T, Nohara R, Ogawa M, Ishino S, Kambara N, Kataoka K, et al. A catheter-based radiation detector for endovascular detection of atheromatous plaques. Eur J Nucl Med Mol Imaging 2004;31:1299–303.PubMedCrossRef

98.

Hosokawa R, Kambara N, Ohba M, Mukai T, Ogawa M, Motomura H, et al. A catheter-based intravascular radiation detector of vulnerable plaques. J Nucl Med 2006;47:863–7.PubMed

Title: Metabolic imaging using PET
Author: Takashi Kudo
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0440-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Metabolic imaging using PET

Abstract

Introduction

Measurement

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Measurement

Discussion

Please log in to get access to this content

Other articles of this Special Issue 1/2007

Imaging of angiogenesis in cardiology

Cardiovascular molecular imaging of apoptosis

Integration of genomics, proteomics, and imaging for cardiac stem cell therapy

Metabolic imaging using SPECT

Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions

Radionuclide reporter gene imaging for cardiac gene therapy